Drug Trial Radar · NCT02480894
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Jul 7, 2015
Primary completion
Sep 21, 2015
Study completion Sep 21, 2015
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jun 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529 when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068Drug
BMS-663068
MaravirocDrug
Maraviroc
Primary outcomes
What the sponsor says the trial is designed to measure.
- BMS-626529 Pharmacokinetics: maximum observed plasma concentration (Cmax)Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
- BMS-626529 Pharmacokinetics: area under the plasma concentration-time curve (AUC) in a single dosing interval AUC(TAU)Time frame: predose and up to 12 hours post dose on Days 4, 16, 17, and 18
- Maraviroc Pharmacokinetics: CmaxTime frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
- Maraviroc Pharmacokinetics: AUC(TAU)Time frame: predose and up to 12 hours post dose on Days 9, 10, 11, 16, 17, and 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.